APA (7th ed.) Citation

K, I., M, T., T, T., K, K., Y, T., K, N., & T, K. (2025). Combination immunotherapy in Japanese patients with advanced renal cell carcinoma: Bridging gaps between clinical trials, real-world evidence, and the potential value of adverse events-a narrative review. Translational cancer research, 14(11), 8142. https://doi.org/10.21037/tcr-2025-1859

Chicago Style (17th ed.) Citation

K, Iinuma, Tomioka M, Taniguchi T, Kawase K, Tobisawa Y, Nakane K, and Koie T. "Combination Immunotherapy in Japanese Patients with Advanced Renal Cell Carcinoma: Bridging Gaps Between Clinical Trials, Real-world Evidence, and the Potential Value of Adverse Events-a Narrative Review." Translational Cancer Research 14, no. 11 (2025): 8142. https://doi.org/10.21037/tcr-2025-1859.

MLA (9th ed.) Citation

K, Iinuma, et al. "Combination Immunotherapy in Japanese Patients with Advanced Renal Cell Carcinoma: Bridging Gaps Between Clinical Trials, Real-world Evidence, and the Potential Value of Adverse Events-a Narrative Review." Translational Cancer Research, vol. 14, no. 11, 2025, p. 8142, https://doi.org/10.21037/tcr-2025-1859.